Pharmaceutical

GSK and Bharat Biotech to Cut Malaria Vaccine Cost GSK Vaccine GSK and Bharat Biotech plan to reduce the cost of Mosquirix, the world’s first WHO-approved malaria vaccine, to under $5 per dose by 2028, aiming to expand global access and support Gavi’s child immunization goals across Africa.
Sanofi and Gilead Expand Protein Degrader Portfolios Sanofi Gilead Sanofi and Gilead deepen their partnerships with Kymera Therapeutics, focusing on next-gen protein degraders for cancer and immune diseases in multi-million dollar deals, signaling rising industry interest.
GSK Strengthens Blenrep's Case with New Data GSK EHA GSK’s Blenrep demonstrates significant progression-free survival improvements in multiple myeloma trials DREAMM-8 and DREAMM-7, strengthening its case for a U.S. market return with FDA decision expected by July 2025.
Global Biopharma Layoffs June 2025 Layoffs Layoff BioNTech Gilead Biopharma layoffs surge in June 2025 as major companies like Genentech, Vertex, and Recursion downsize. Explore the latest job cuts, site closures, and restructuring trends across the industry.
Merck KGaA Lupus Drug Trial Update: Enpatoran Phase 2 Insights Merck Autoimmune Merck KGaA reveals detailed results from its phase 2 lupus trial of enpatoran, highlighting mixed outcomes in different patient cohorts and plans to pursue regulatory approval based on promising secondary endpoint data.
Insmed Advances TPIP with Phase 2b PAH Success Insmed Insmed reports strong Phase 2b results for TPIP in pulmonary arterial hypertension (PAH), showing significant efficacy and safety. The company plans to launch Phase 3 trials in PAH and PH-ILD by 2026.
Nuvation Bio's Ibtrozi Gains FDA Nod to Compete in Lung Cancer Market FDA Nuvation Bio Cancer Nuvation Bio’s Ibtrozi (taletrectinib) secures FDA approval for treating ROS1-positive non-small cell lung cancer, offering a next-gen alternative to Pfizer, BMS, and Roche therapies with strong efficacy and CNS safety.
Bristol Myers Squibb Bets on ACP3 in $1.35B Deal BMS Biotech Philochem Bristol Myers Squibb teams up with Philochem in a $1.35B radiopharma deal to develop OncoACP3, a novel prostate cancer therapy targeting ACP3, offering a potential alternative to PSMA-focused treatments.
Shanghai-Suzhou: Biopharma's Next hub? Market Trend As the global race in the biopharmaceutical industry accelerates, the Shanghai-Suzhou cluster is emerging as a powerful contender. Ranked 9th worldwide by the 2024 MedCity report, this dynamic duo from China is challenging the dominance of legacy giants like Boston, NewYork, and London.
Elevation Oncology Acquired After Ending Partnership with CSPC CSPC Elevation Oncology Elevation Oncology has been acquired by Concentra Biosciences after halting its Claudin18.2 ADC program with CSPC. The deal includes a $22M valuation and future rights tied to EO-1022, its sole remaining HER3-targeted ADC candidate.

< Pre 1...42 43 444546 47 48...87 Next >

Articles Archives

Hot Articles

Related Exhibition

All Categories

Agri & Industry Cosmetic Food History Laboratory

HOT Topics

Hot Articles